Scientists from Creative Biolabs have successfully built up a unique platform to develop high-affinity bovine monoclonal antibodies with ultralong CDR3s.
Scientists from Creative Biolabs have successfully built up a unique platform to develop high-affinity bovine monoclonal antibodies with ultralong CDR3s.
Apexigen is a pioneer biotech company for antibody therapeutics based on rabbit-derived humanized monoclonal antibodies, allowing therapeutic benefits that have not been achieved through the use of other technologies. Thanks to its proprietary platform technology, Apexigen has built a strong pipeline of humanized monoclonal antibody programs spanning from oncology, inflammatory disease and ophthalmology.